|
1）Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63: 2935-59
|
|
|
|
2）Stone NJU, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63: 2889-934
|
|
|
|
|
|
3）Cleeman JI, Grundy SM, Becker D, et al. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-97
|
|
|
|
|
|
4）Martin SS, Abd TT, Jones SR, et al. 2013 ACC/AHA Cholesterol Treatment Guideline. What was done well and what could be done better. JACC. 2014; 63: 2789-94
|
|
|
|
|
|
5）Breslow JL. Perspective on the 2013 American Heart Association/American College of Cardiology guideline for the use of statins in primary prevention of low-risk individuals. Circ Res. 2014; 114: 758-60
|
|
|
|
|
|
6）NLA Statement on the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Available at: https://www.lipid.org/nla/2013-accaha-guidelinetreatment-blood-cholesterol-reduce-atherosclerotic-cardiovascular-risk. Accessed July. 9, 2014
|
|
|
|
|
|
7）AACE Press Statement on 2013 ACC/AHA Guidelines. Available at: http://media.aace.com/press-release/press-statement. Accessed July 9, 2014
|
|
|
|
|
|
8）Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013; 382: 1762-5
|
|
|
|
|
|
9）Vaucher J, Marques-Vidal P, Preisig M, et al. Population and economic impact of the 2013 ACC/AHA guidelines compared with European guidelines to prevent cardiovascular disease. Eur Heart J. 2014; 35: 958-9
|
|
|
|
|
|
10）Ioannidis JPA. More than a billion people taking statins? Potential implications of the new cardiovascular guidelines. JAMA. 2014; 311: 463-4
|
|
|
|
|
|
11）Amin NP, Martin SS, Blaha MJ, et al. Headed in the right direction but at risk for miscalculation: a critical appraisal of the 2013 ACC/AHA risk assessment guidelines. J Am Coll Cardiol. 2014; 63: 2789-94
|
|
|
|
|
|
12）日本動脈硬化学会．ACC/AHAガイドラインに対する日本動脈硬化学会の見解 2014年2月1日 http://www.j-athero.org/outline/guideline_comment.html
|
|
|
|
|
|
13）Yamamoto T, Nakamura Y, Hozawa A, et al. NIPPON DATA80 Research Group. Low-risk profile for cardiovascular disease and mortality in Japanese. Circ J. 2008; 72: 545-50
|
|
|
|
|
14）Reiner Z, Catapano AL,DeBacker G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011; 32: 1769-818
|
|
|
|
|
|
15）Ray KK, Kastelein JJP, Boekholdt SM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014; 35: 960-8
|
|
|
|
|
|
16）JBS3. Joint British Societies’ consensus recommendations for the prevention of cardiovascular diseases (JBS3). Heart. 2014; 100: ii1-6
|
|
|
|
|
|
17）National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Draft for consultation, February 2014
|
|
|
|
|
|
18）An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia. Available at: http://www.athero.org/download/IASPPGuidelines_FullReport_2.pdf. Accessed July 9, 2014
|
|
|
|
|